Oncology: Prostate
Joseph Wagner, MD
Hartford HealthCare/University of Connecticut
Matthew Cooperberg, MD
UCSF Helen Diller Family Comprehensive Cancer Center
Daniel Lin, MD (he/him/his)
University of Washington
Course Description: There are multiple genomic tests currently available for men to detect and risk-stratify prostate cancer. The outcomes of these tests may lead to different detection strategies (observation, immediate biopsy, MRI, etc.) and treatment decisions (active surveillance, surgery, radiation, adjuvant therapy, etc.). We will also discuss germline testing as inherited mutations have considerable implications for screening, treatment, genetic counseling and cascade testing of family members.
The availability and marketing of genomic testing have outpaced a reflective, evidence-based medicine approach to using these tests. Discussing the research studies that led to the approval of the various genomic tests, understanding the prognostic clinical end points they predict, reviewing current AUA and National Comprehensive Cancer Network® Guidelines for prostate cancer genomic testing, examining available validation studies and utilizing case-based scenarios will provide participants with the knowledge to assess these tests and apply them to their clinical practice.